Horby PW, Estcourt L, Peto L, et al. - By conducting this randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), researchers examined whether convalescent plasma therapy is safe as well as efficacious for treatment of patients admitted to hospital with COVID-19. Randomization (1:1) of eligible and consenting patients was done to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). It was found that 28-day mortality did not differ significantly between the two groups. Findings revealed that no improvement in survival or in other prespecified clinical outcomes was conferred by high-titre convalescent plasma therapy in patients hospitalised with COVID-19.